US stock · Healthcare sector · Medical Devices
Company Logo

DexCom, Inc.

DXCMNASDAQ

106.72

USD
+0.07
(+0.07%)
Market Closed
237.16P/E
102Forward P/E
11.92P/E to S&P500
41.221BMarket CAP
- -Div Yield
Upcoming Earnings
9 Feb
Shares Short
1/13/23
11.77M
Short % of Float
3.43%
Short % of Shares Outs.
3.05%
% Held by Insiders
0.42%
% Held by Institutions
100.55%
Beta
1.16
PEG Ratio
3.82
52w. high/low
134.76/66.89
Avg. Daily Volume
2.60M
Return %
Stock
S&P 500
1 year
7.25
(6.69)
3 years
80.97
24.70
5 years
630.96
43.94
Scale: |
High
Low
2.51
0.34
2.24
0.66
3.62
2.05
4.23
1.69
3.87
2.16
8.99
3.42
14.58
7.02
25.82
13.32
24.09
11.98
22.20
10.65
38.03
12.76
58.00
26.86
114.06
45.52
164.86
79.61
134.76
66.89
117.54
102.50
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
0.02
0.04
0.08
0.17
0.21
0.29
0.36
0.56
0.86
1.26
1.71
2.08
2.92
4.05
5.10
6.33
7.17
Earnings per share
(0.43)
(0.41)
(0.47)
(0.30)
(0.24)
(0.17)
(0.20)
(0.10)
(0.07)
(0.18)
(0.20)
(0.15)
(0.36)
0.28
1.31
0.40
0.59
FCF per share
(0.43)
(0.32)
(0.34)
(0.24)
(0.22)
(0.15)
(0.16)
(0.02)
0.02
0.05
0.00
0.08
0.16
0.37
0.73
0.14
0.67
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.03
0.03
0.02
0.02
0.03
0.03
0.03
0.03
0.05
0.10
0.17
0.19
0.19
0.49
0.53
1.01
0.98
Book Value per sh.
0.52
0.06
(0.33)
(0.10)
0.27
0.40
0.28
0.30
0.47
0.69
0.85
1.21
1.88
2.42
4.84
5.82
5.47
Comm.Shares outs.
109
113
118
177
228
262
275
284
301
319
334
345
353
364
378
387
390
Avg. annual P/E ratio
- -
(5.2)
(3.3)
(4.9)
(11.6)
(19.2)
(15.0)
(54.0)
(139.3)
(104.1)
(93.6)
(117.6)
(67.6)
135.9
65.3
289.1
237.2
P/E to S&P500
- -
(0.3)
(0.2)
(0.1)
(0.6)
(1.2)
(1.0)
(3.2)
(7.7)
(5.2)
(4.2)
(5.0)
(2.7)
5.6
1.7
9.6
11.9
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
2
5
10
30
49
76
100
160
259
402
573
719
1,032
1,476
1,927
2,449
2,793
Operating margin
(2,273.0)%
(1,008.8)%
(537.0)%
(154.4)%
(93.1)%
(58.8)%
(55.8)%
(18.1)%
(8.3)%
(14.2)%
(11.1)%
(5.9)%
(18.1)%
9.6%
15.5%
10.9%
9.2%
Depreciation (m)
3
3
4
2
2
4
7
7
8
11
15
16
29
49
67
102
152
Net profit (m)
(47)
(46)
(55)
(54)
(55)
(45)
(55)
(30)
(22)
(58)
(66)
(50)
(127)
101
494
155
230
Income tax rate
- -
- -
- -
- -
- -
- -
2.3%
- -
(0.4)%
(0.2)%
(1.1)%
(3.3)%
(0.5)%
3.0%
(119.4)%
11.0%
(34.6)%
Net profit margin
(2,147.6)%
(991.5)%
(560.9)%
(180.3)%
(113.4)%
(58.7)%
(54.6)%
(18.6)%
(8.6)%
(14.3)%
(11.4)%
(7.0)%
(12.3)%
6.8%
25.6%
6.3%
8.3%
Working capital (m)
52
59
17
18
51
90
58
61
105
164
178
606
1,477
1,609
2,811
2,964
2,498
Long-term debt (m)
2
61
61
46
- -
- -
7
5
2
- -
- -
334
1,018
1,147
1,823
1,858
2,111
Equity (m)
57
7
(39)
(18)
61
104
77
84
140
221
284
419
663
883
1,827
2,252
1,825
ROIC
- -
- -
- -
- -
- -
- -
(62.8)%
(32.0)%
(15.0)%
(25.4)%
(21.6)%
(4.8)%
(6.2)%
7.8%
18.5%
5.9%
9.6%
Return on capital
(72.2)%
(59.4)%
(124.4)%
(96.9)%
(69.5)%
(37.1)%
(52.5)%
(23.6)%
(11.6)%
(19.6)%
(15.9)%
(4.0)%
(5.4)%
6.9%
7.2%
5.7%
5.8%
Return on equity
(82.0)%
(644.8)%
142.9%
290.2%
(90.5)%
(42.8)%
(70.8)%
(35.4)%
(16.0)%
(26.0)%
(23.1)%
(12.0)%
(19.2)%
11.5%
27.0%
6.9%
12.6%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(8.8)%
(5.5)%
(38.1)%
(8.6)%
Capital Structure
27 Oct · 2022 | Q3
All numbers in millions
Total liabilities
$ 3,075
Total assets
$ 4,899
Long-term debt
$ 2,111
Cash and equiv.
$ 698
Goodwill
$ 25
Retained earnings
$ 388
Common stock
390
Enterprise Value
$ 42,635
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
1,533
2,708
2,731
Receivables
286
429
514
Inventory
120
235
357
Other
30
425
688
Current assets
1,969
3,425
3,684
Acc. Payable
102
163
196
Debt due
14
17
21
Other
244
434
504
Current liabilities
360
614
721
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
27.08%
36.07%
43.27%
Cash flow
(80.73)%
70.11%
563.79%
Earnings
(68.66)%
73.30%
41.18%
Dividends
- -
- -
- -
Book value
23.27%
55.36%
47.91%
Insider Trading
Type
Shares
Date
Pacelli Steven Robert
Sale
412
01/23/23
Sayer Kevin R
Sale
45,607
01/20/23
Sayer Kevin R
Award
90,720
01/18/23
Pacelli Steven Robert
Sale
412
12/23/22
Flynn Paul R
Sale
8,988
12/08/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
405
452
501
569
1,927
2021
505
595
650
698
2,449
2022
629
696
770
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.05
0.12
0.19
0.94
1.31
2021
0.10
0.16
0.18
(0.05)
0.40
2022
0.25
0.13
0.26
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Kevin Sayer
Full-time employees:
6,300
City:
San Diego
Address:
6340 Sequence Dr
IPO:
Apr 14, 2005
Website:
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.